Phase I trial of radiochemotherapy with bendamustine in patients with recurrent squamous cell carcinoma of the head and neck

Strahlentherapie und Onkologie

Volumn 183, Issue 3, 2007, Pages 128-132

  Bottke, Dirk ^a   Bathe, Kathrin ^b   Wiegel, Thomas ^a   Hinkelbein, Wolfgang ^b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Bendamustine; Head and neck cancer; Phase I study; Radiochemotherapy; Toxicities

Indexed keywords

BENDAMUSTINE; CARBOPLATIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXICITY; DRUG DOSE INCREASE; DRUG TOLERABILITY; FEMALE; GRANULOCYTOPENIA; HEAD AND NECK CARCINOMA; HUMAN; INFECTION; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 1 CLINICAL TRIAL; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NITROGEN MUSTARD COMPOUNDS; OTORHINOLARYNGOLOGIC NEOPLASMS;

EID: 33847649503     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-007-1597-1     Document Type: Article

References (33)

1. Aivado M, Schulte K, Henze L, et al. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Semin Oncol 2002;29:19-22.
2. Dawson LA, Myers LL, Bradford CR, et al. Conformal re-irradiation of recurrent and new primary head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:377-85.
3. Ernst-Stecken A, Grabenbauer G, Iro H, et al. Phase II trial of hyperfractionated accelerated split-course radiochemotherapy with 5-FU and cis-DDP in advanced head and neck cancer. Strahlenther Onkol 2004;180:805-10.
4. Gandhi V. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin Oncol 2002;29:15-8.
5. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med 1995;14:1149.
6. Harwood AR, Tierie A. Radiotherapy of early glottic cancer - II. Int J Radiat Oncol Biol Phys 1979;5:477-82.
7. Hehr T, Budach W, Belka C, et al. Alternating radio-chemotherapy with docetaxel/DDP and involved field radiotherapy for recurrent, inoperable, and previously irradiated head and neck cancer. Eur J Cancer 2001;37:Suppl 6:S107.
8. Hehr T, Classen J, Belka C, et al. Reirradiation alternating with doxetaxel and cisplatin in inoperable recurrence of head-and-neck cancer: a prospective phase I/II trial. Int J Radiat Oncol Biol Phys 2005;61:1423-31.
9. Heider A, Köster W, Grote-Kiehn J, et al. Bendamustine in untreated small cell lung cancer (SCLC): efficacy and toxicity. Eur J Cancer 1999;35:Suppl 4:254.
10. Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs 2001;12:725-9.
11. Hesse K, Heinrich B, Zimmermann F, et al. Combined radiochemotherapy with docetaxel in patients with unresectable locally advanced head and neck tumors. Strahlenther Onkol 2000;176:67-72.
12. Hoff DD von, Kuhn J, Clark GM. Design and conduct of phase I trials. In: Buyse ME, Staquet MJ, Sylvester RJ, eds. Cancer clinical trials - methods and practice. Oxford: Oxford University Press, 1988:210-20.
13. Höffken K, Merkle K, Schönfelder M, et al. Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study. J Cancer Res Clin Oncol 1998;124:627-32.
14. Hoeller U, Biertz I, Flinzberg S, et al. Hyperfractionated-accelerated radiotherapy followed by radical surgery in locally advanced tumors of the oral cavity. Strahlenther Onkol 2006;182:157-63.
15. Jereczek-Fossa BA, Morra A, DeBraud F, et al. Hyperfractionated radiotherapy in locally advanced nasopharyngeal cancer. Strahlenther Onkol 2004;180:425-33.
16. Köster W, Rudolph R, Stahl M. Bendamustine (Ribomustin) chemotherapy in platinum pretreated small cell lung cancer patients (extensive disease). J Cancer Res Clin Oncol 2002;128:Suppl 1:P370.
17. Kovács AF, Mose S, Böttcher HD, et al. Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer. Strahlenther Onkol 2005;181:26-34.
18. Kuhnt T, Becker A, Pigorsch S, et al. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial. Strahlenther Onkol 2003;179:673-81.
19. Leventhal BG, Wittes RE. Research methods in clinical oncology. New York: Raven Press, 1988:41-59.
20. Merlano M, Russi EG, Numico G, et al. Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck. A phase II trial. Radiother Oncol 2005;75:193-6.
21. Merlano M, Vitale V, Rosso R, et al. Treatment of advanced squamous cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med 1992;327:1115-21.
22. Milano MT, Vokes EE, Salama JK, et al. Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. Int J Radiat Oncol Biol Phys 2005;61:1096-106.
23. Minckwitz G von, Chernozemsky I, Souchon R, et al. First-line treatment of patients wit metastatic breast cancer. Analysis of an international prospective randomised multicenter phase III trial comparing bendamustine, methotrexate and 5-FU (BMF) versus CMF under consideration of elderly patients. J Cancer Res Clin Oncol 2004;130:Suppl 1:AS 920.
24. O'Quigley J, Chevret S. Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study. Stat Med 1991;10:1647.
25. Paulsen F, Scheiderbauer J, Eschmann SM, et al. First experiences of radiation treatment planning with PET/CT. Strahlenther Onkol 2006;182:369-75.
26. Pönisch W, Niederwieser D. Bendamustine in the treatment of multiple myeloma: results and future perspectives. Semin Oncol 2002;29:23-6.
27. Rahn AN, Schilcher RB, Adamietz IA, et al. Palliative Radiochemotherapie mit Bendamustin bei fortgeschrittenen Tumorrezidiven im HNO-Bereich. Strahlenther Onkol 2001;177:189-94.
28. Reck M, Haering B, Koschel G, et al. Chemotherapie des fortgeschrittenen kleinzelligen und nichtkleinzelligen Bronchialkarzinoms mit Bendamustin. Eine Phase II Studie. Pneumologie 1998;52:571-4.
29. Reichmann U, Huober J, Boekemeyer C, et al. Salvage therapy for metastatic breast cancer: results of a phase II study with bendamustine. Onkologie 2004;27:Suppl 2:38.
30. Rummel MJ, Mitrou PS, Hoelzer D. Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives. Semin Oncol 2002;29:27-32.
31. Spencer SA, Harris J, Wheeler RH, et al. RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys 2001;51:1299-304.
32. Studer G, Studer SP, Zwahlen RA, et al. Osteoradionecrosis of the mandible: minimized risk profile following intensity-modulated radiation therapy (IMRT). Strahlenther Onkol 2006;182:283-8.
33. Wendt TG, Grabenbauer GG, Rödel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16:1318-24.